YBYemima Berman

Yemima Berman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yemima Berman has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Outcome measures for cutaneous neurofibromas in NF1 : Insights from an international study

    by Christina Bergqvist, Laura Fertitta, Soulef Mehri, Sabine Moryousef, Houda Ayache, Salah Ferkal, Jane Fleming, Carlos Romo, Yemima Berman, Khaled Ezzedine, et al.

  • Reproductive decision‐making experiences of Australian adults with neurofibromatosis type 1 and schwannomatosis

    by Tina Gonzalez, Alison McLean, Jane Fleming, Katrina Morris, Melissa Pacque, Caitlin Forwood, Claire Wong, Sue‐Faye Siow, Sarah Barter, Kristi J. Jones, et al.

    Individuals with neurofibromatosis type 1 and schwannomatosis (NF) often face difficult reproductive choices when family planning; however, their experiences and the barriers and enablers to reproductive decision‐making are poorly understood. The purpose of this study was to explore the opinions and experiences of individuals with NF in Australia and inform the development of practice recommendations and resources. Focus groups with adults with NF were conducted using a semi‐structured interview schedule developed by the research team. Partners were also invited. The focus groups were recorded, de‐identified, transcribed, and analyzed using codebook thematic analysis. Three focus groups were conducted with 17 participants (12 = NF1, 4 = NF2‐related schwannomatosis [NF2‐SWN] and one partner). Three themes were identified: (1) Barriers and enablers; (2) Contemplating the options; and (3) Education and support needs. Barriers to reproductive decision‐making included: difficulty accessing healthcare services to discuss reproductive planning; a lack of access to reliable information sources and support; and, in some cases, the financial cost of assistive reproductive technology. Conversely, positive healthcare experiences and support systems enabled reproductive choices. Participants reported many factors that contributed to their reproductive decisions, including: their personal experience of their condition; concern about their future health and that of an affected child; the impact of pregnancy on their health; and the opinion of healthcare providers, family, and friends. Many participants reported mental health difficulties related to their condition and additional stressors related to the reproductive journey. Participants' recommendations included increased access to healthcare services to discuss reproductive options, the development of comprehensive information resources, and improved psychological and peer support for individuals with NF considering family planning and, where relevant, their partners. In conclusion, people with NF and their partners identify a need for improved awareness of NF among healthcare professionals and increased access to appropriate services, information, and support to facilitate informed reproductive decision‐making.


  • Open Access

    Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1

    by Jonathan C. L. Lau, Jane Fleming, Martin Good, Adrian Lim, Rebecca B. Saunderson, Tai A. Phan, Timothy Schlub, Sue‐Faye Siow, Nanette Lacson, Carlos Romo, et al.

    Background: Cutaneous neurofibromas (cNFs) are a major cause of disfigurement in patients with Neurofibromatosis Type 1 (NF1). However, clinical trials investigating cNF treatments lack standardised outcome measures to objectively evaluate changes in cNF size and appearance. 3D imaging has been proposed as an objective standardised outcome measure however various systems exist with different features that affect useability in clinical settings. The aim of this study was to compare the accuracy, precision, feasibility, reliability and accessibility of three imaging systems. Materials and methods: We compared the Vectra‐H1, LifeViz‐Micro and Cherry‐Imaging systems. A total of 58 cNFs from 13 participants with NF1 were selected for imaging and analysis. The primary endpoint was accuracy as measured by comparison of measurements between imaging systems. Secondary endpoints included reliability between two operators, precision as measured with the average coefficient of variation, feasibility as determined by time to capture and analyse an image and accessibility as determined by cost. Results: There was no significant difference in accuracy between the three devices for length or surface area measurements ( p > 0.05), and reliability and precision were similar. Volume measurements demonstrated the most variability compared to other measurements; LifeViz‐Micro demonstrated the least measurement variability for surface area and image capture and analysis were fastest with LifeViz‐Micro. LifeViz‐Micro was better for imaging smaller number of cNFs (1–3), Vectra‐H1 better for larger areas and Cherry for uneven surfaces. Conclusions: All systems demonstrated excellent reliability but possess distinct advantages and limitations. Surface area is the most consistent and reliable parameter for measuring cNF size in clinical trials.


  • Open Access

    The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1

    by Brieana Dance, Alice Dardare, Jane Fleming, Sue‐Faye Siow, Timothy E. Schlub, Hilda Crawford, Rebecca B. Saunderson, Claire Wong, Yemima Berman

    The skin manifestations of neurofibromatosis 1 significantly reduce health‐related quality‐of‐life. However, data on the utility of existing surveys in capturing neurofibromatosis 1 skin treatment outcomes are lacking. This quantitative study examined the relationship between clinician‐rated severity and visibility and patient‐rated itch and quality‐of‐life (QoL) to (1) establish baseline levels of skin‐ and condition‐specific‐related QoL, itch, depression and anxiety; (2) identify patient concerns to inform the development and evaluation of skin interventions; and (3) compare the sensitivity of different QoL measures. Validated scales included Skindex‐29, Dermatology Life Quality Index (DLQI), Neurofibromatosis 1‐adult quality‐of‐life (NF1‐AdQOL) questionnaire, and the Hospital Anxiety and Depression Scale (HADS). We recruited 100 participants (response rate: 95%). Of these, 42% reported itch and 23% had probable clinical anxiety. Our cohort had higher levels of anxiety and total HADS scores compared to a control population. Using multivariate regression analysis, increasing visibility significantly predicted poorer QoL using the Skindex‐29, NF1‐AdQOL, and DLQI (p < 0.05); and itch significantly predicted worse QoL in Skindex‐29 and NF1‐AdQOL (p < 0.05). The highest mean scoring questions in Skindex‐29 and NF1‐AdQOL concerned worry about worsening skin disease and embarrassment. The highest mean scoring questions in DLQI were regarding itch, pain, and embarrassment. Items asking specifically about cutaneous neurofibromas (cNF) scored higher than comparable skin‐specific questions (t‐test p value <0.05). In summary, this study provides insights into the factors contributing to impaired QoL, anxiety, and mood in NF1 patients with cutaneous neurofibromas. Key factors identified for use in cNF measures include visibility, itch, anxiety, embarrassment, fears of worsening skin disease, and cNF‐specific questions.


  • Open Access

    2646 Neurofibromatosis model of care project – development of a state-wide integrated value-based model of care for the neurofibromatoses

    by Sue-Faye Siow, Jane Fleming, Hossai Gul, Manoj P Menezes, Martin Good, Suzana Milosavljevic, Sally Maspero, Tina Gonzalez, Claire Wong, Kristi Jones, et al.

    Background The Neurofibromatoses (NF) are a group of inherited conditions that predispose to nerve sheath tumours with multi-system involvement and complex care needs. A recent survey has revealed NF patients have difficulty accessing specialised multidisciplinary NF care resulting in concerns for suboptimal patient management and health outcomes.Objectives The paediatric and adult centralised NF services in NSW collaborated to design and implement an innovative model of care for patients with NF in NSW.Methods A logic model was combined with a clinical redesign framework to guide the development and implementation of an innovative model of care via a mixed method multiphase design. An initial stakeholder workshop, stakeholder surveys (n=47) and interviews (n=21) were used to map out the current model of care, identify areas for improvement, and propose new solutions. A networked model of care was designed based on stakeholder feedback and implemented. A final stakeholder workshop (n=24) was held to assess stakeholder feedback on the new model and interventions to recognise areas for further development.Results The interventions implemented included: nurse-led care, statewide NF virtual multidisciplinary meetings, joint paediatric-adult NF transition clinic, and NF outreach clinic. Resources developed to support these interventions were referral criteria for centralised NF services, referral pathways, GP and patient resources, centralised NF website, and transition care guidelines.Conclusions A networked model of care was implemented to provide equitable access to comprehensive care for patients with NF. Measurement of outcomes are underway with clinical audits and patient surveys to evaluate effectiveness of these interventions.

  • Clinical and imaging modality factors impacting radiological interpretation of breast screening in young women with neurofibromatosis type 1

    by Mathilda Wilding, Jane Fleming, Katrina Moore, Ashley Crook, Ranjani Reddy, Sarah Choi, Timothy E. Schlub, Michael Field, Lavvina Thiyagarajan, Jeff Thompson, et al.

    Young women with Neurofibromatosis type 1 (NF1) have a high risk of developing breast cancer and poorer survival following breast cancer diagnosis. International guidelines recommend commencing breast screening between 30 and 35 years; however, the optimal screening modality is unestablished, and previous reports suggest that breast imaging may be complicated by the presence of intramammary and cutaneous neurofibromas (cNFs). The aim of this study was to explore potential barriers to implementation of breast screening for young women with NF1. Twenty-seven women (30–47 years) with NF1 completed breast screening with breast MRI, mammogram and breast ultrasound. Nineteen probably benign/suspicious lesions were detected across 14 women. Despite the presence of breast cNFs, initial biopsy rate for participants with NF1 (37%), were comparable to a BRCA pathogenic variant (PV) cohort (25%) (P = 0.311). No cancers or intramammary neurofibromas were identified. Most participants (89%) returned for second round screening. The presence of cNF did not affect clinician confidence in 3D mammogram interpretation, although increasing breast density, frequently seen in young women, impeded confidence for 2D and 3D mammogram. Moderate or marked background parenchymal enhancement on MRI was higher in the NF1 cohort (70.4%) than BRCA PV carriers (47.3%), which is an independent risk factor for breast cancer. Breast MRI was the preferred mode of screening over mammogram, as the majority (85%) with NF1 demonstrated breast density (BI-RADS 3C/4D), which hinders mammogram interpretation. For those with high breast density and high cNF breast coverage, 3D rather than 2D mammogram is preferred, if MRI is unavailable.


  • Current and Emerging Imaging Techniques for Neurofibromatosis Type 1–Associated Cutaneous Neurofibromas

    by Yingjoy Li, Jaishri O. Blakeley, Ina Ly, Yemima Berman, Jonathan Lau, Pierre Wolkenstein, Christina Bergqvist, Wangcun Jia, Thomas E. Milner, Nitesh Katta, et al.


  • Open Access

    Characterization of health concerns in people with neurofibromatosis type 1

    by Jane Fleming, Oliver Morgan, Claire Wong, Timothy E. Schlub, Yemima Berman

    Background: Neurofibromatosis 1 (NF1) is a common cancer predisposition syndrome. Affected individuals require lifelong surveillance and often suffer progressive disfigurement due to cutaneous neurofibromas. The aim of this research was to characterize health concerns and quality of life (QOL) in a population cohort.Methods: An online survey was completed by 68 adults and 32 parents of children with NF1, and 60 controls. The survey included the Skindex‐29 QOL scale, 5D‐itch scale, and additional health questions.Results: Frequency of itch was high in children (50%) and adults (69%), with most expressing interest in treatment for itch. The presence of itch and increased visibility of NF1 were predictors of poorer QoL. Many adults (53%) and parents (44%) desired access to treatment to improve cosmetic appearance. Muscle weakness/tiredness was also prevalent amongst (60–70%) adults and children with NF1. Two‐thirds of adults with NF1 reported limited awareness of NF1 services and poor knowledge of surveillance, particularly breast screening in young women.Conclusion: This study highlights the impact of NF1‐related itch and visibility in adults and children with a need for cosmetic and itch treatment. The findings emphasize a need for strategies to promote awareness, and access to management and treatment of NF1 in adults.


  • Open Access

    Evaluating the model of offering expanded genetic carrier screening to high school students within the Sydney Jewish community

    by Kristine Barlow-Stewart, Kayley Bardsley, Elle Elan, Jane Fleming, Yemima Berman, Ron Fleischer, Krista Recsei, Daniel Goldberg, John Tucker, Leslie Burnett

    Programs offering reproductive genetic carrier screening (RGCS) to high school students within the Ashkenazi Jewish community in several countries including Canada and Australia have demonstrated high uptake and retention of educational messages over time. This study was undertaken to evaluate whether testing for an expanded number of conditions in a high school setting would impact the effectiveness of education. In this questionnaire-based study, genetic carrier testing for nine conditions was offered to 322 year 11 students from five high schools, with students attending a compulsory 1-h education session prior to voluntary testing. Comparison of pre- and post-education measures demonstrated a significant increase in knowledge, positive attitudes, and reduced concern immediately after the education session. Retention of knowledge, measures of positive attitude, and low concern over a 12-month period were significantly higher than baseline, although there was some reduction over time. In total, 77% of students exhibited informed choice regarding their intention to test. A significant increase in baseline knowledge scores and positive attitude was also demonstrated between our original 1995 evaluation (with testing for only one condition) and 2014 (testing for nine conditions) suggesting community awareness and attitudes to RGCS have increased. These findings validate the implementation of effective education programs as a key component of RGCS and are relevant as gene panels expand with the introduction of genomic technologies.


  • Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1

    by Sheilagh Maguiness, Yemima Berman, Nathan Rubin, Melissa Dodds, Scott R. Plotkin, Claire Wong, Christopher Moertel, on behalf of the REiNS International Collaboration

    Objective In order to explore the use of Skindex scoring in patients with neurofibromatosis type 1 (NF1) across multiple clinical sites and inform design of additional quality of life measures, we analyzed correlations between Skindex, site, and clinical measures for 79 patients with NF1 from specialized clinics in Sydney, Australia (Royal North Shore Hospital [RNS]) and Minneapolis, Minnesota (University of Minnesota [UMN]). Methods The relationship between clinical factors and Skindex scores were explored by clinic site and overall. Results A total of 40 participants were recruited from RNS and 39 from UMN. Female sex, total number of cutaneous neurofibroma (cNF), and whether cNF were present on the face correlated highly with Skindex and not Riccardi scores. The UMN site had lower average scores, but these differences were almost entirely removed after adjusting for age, sex, facial cNF, and total cNF number. Conclusions The development of cNF in adolescence and adulthood in NF1 often leads to progressive disfigurement and discomfort and is among one of the most common reasons for patients to seek medical treatment. Skindex has been used to assess skin-related quality of life in NF1 previously but is not specific to NF1. These findings highlight the need for a low threshold for referral to dermatologists for all patients with NF1 regardless of the severity of disease. The finding that facial cNF and higher total number of cNF correlates with poorer skin-related quality of life may benefit design of more specific NF1 skin-related quality of life measures.